Year in review: Transcatheter aortic valve replacement

Meng-Ta Tsai, Gilbert H.L. Tang, Gideon N. Cohen

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Purpose of review Transcatheter aortic valve replacement (TAVR) has been effective in prohibitive/high-risk patients. Expansion toward intermediate or even low-risk patients has been proposed. A review of recent developments will help understand current trends and issues. Recent findings The 5-year results from the PARTNER I trial and 2-year results of the CoreValve US Pivotal Trial, together with national registries, confirmed the long-term efficacy and durability of TAVR. Studies including PARTNER II, ADVANCE, and The German Aortic Valve Registry showed short-to mid-term success in intermediate-risk patients. Comparison of balloon-expandable and self-expanding valves in the CHOICE trial associated specific outcome differences with specific valve types, suggesting a more customized approach in valve selection. Short-term results of newer-generation valves have demonstrated excellent safety and efficacy with improved designs. Studies on TAVR-specific complications, such as conduction block and arrhythmia, paravalvular aortic regurgitation, and stroke, have renewed ideas about their prognosis, treatment, and prevention. Conscious sedation percutaneous TAVR has become more popular, with excellent outcomes and improved cost savings. Summary TAVR has been accepted as an effective treatment even for intermediate-risk patients. This article aims to review the most recent results and essential issues.

Original languageEnglish
Pages (from-to)139-147
Number of pages9
JournalCurrent Opinion in Cardiology
Volume31
Issue number2
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Registries
Conscious Sedation
Aortic Valve Insufficiency
Cost Savings
Aortic Valve
Cardiac Arrhythmias
Stroke
Transcatheter Aortic Valve Replacement
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Tsai, Meng-Ta ; Tang, Gilbert H.L. ; Cohen, Gideon N. / Year in review : Transcatheter aortic valve replacement. In: Current Opinion in Cardiology. 2016 ; Vol. 31, No. 2. pp. 139-147.
@article{eb11aa07e9e74a68a52aa4763af67334,
title = "Year in review: Transcatheter aortic valve replacement",
abstract = "Purpose of review Transcatheter aortic valve replacement (TAVR) has been effective in prohibitive/high-risk patients. Expansion toward intermediate or even low-risk patients has been proposed. A review of recent developments will help understand current trends and issues. Recent findings The 5-year results from the PARTNER I trial and 2-year results of the CoreValve US Pivotal Trial, together with national registries, confirmed the long-term efficacy and durability of TAVR. Studies including PARTNER II, ADVANCE, and The German Aortic Valve Registry showed short-to mid-term success in intermediate-risk patients. Comparison of balloon-expandable and self-expanding valves in the CHOICE trial associated specific outcome differences with specific valve types, suggesting a more customized approach in valve selection. Short-term results of newer-generation valves have demonstrated excellent safety and efficacy with improved designs. Studies on TAVR-specific complications, such as conduction block and arrhythmia, paravalvular aortic regurgitation, and stroke, have renewed ideas about their prognosis, treatment, and prevention. Conscious sedation percutaneous TAVR has become more popular, with excellent outcomes and improved cost savings. Summary TAVR has been accepted as an effective treatment even for intermediate-risk patients. This article aims to review the most recent results and essential issues.",
author = "Meng-Ta Tsai and Tang, {Gilbert H.L.} and Cohen, {Gideon N.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1097/HCO.0000000000000260",
language = "English",
volume = "31",
pages = "139--147",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Year in review : Transcatheter aortic valve replacement. / Tsai, Meng-Ta; Tang, Gilbert H.L.; Cohen, Gideon N.

In: Current Opinion in Cardiology, Vol. 31, No. 2, 01.03.2016, p. 139-147.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Year in review

T2 - Transcatheter aortic valve replacement

AU - Tsai, Meng-Ta

AU - Tang, Gilbert H.L.

AU - Cohen, Gideon N.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose of review Transcatheter aortic valve replacement (TAVR) has been effective in prohibitive/high-risk patients. Expansion toward intermediate or even low-risk patients has been proposed. A review of recent developments will help understand current trends and issues. Recent findings The 5-year results from the PARTNER I trial and 2-year results of the CoreValve US Pivotal Trial, together with national registries, confirmed the long-term efficacy and durability of TAVR. Studies including PARTNER II, ADVANCE, and The German Aortic Valve Registry showed short-to mid-term success in intermediate-risk patients. Comparison of balloon-expandable and self-expanding valves in the CHOICE trial associated specific outcome differences with specific valve types, suggesting a more customized approach in valve selection. Short-term results of newer-generation valves have demonstrated excellent safety and efficacy with improved designs. Studies on TAVR-specific complications, such as conduction block and arrhythmia, paravalvular aortic regurgitation, and stroke, have renewed ideas about their prognosis, treatment, and prevention. Conscious sedation percutaneous TAVR has become more popular, with excellent outcomes and improved cost savings. Summary TAVR has been accepted as an effective treatment even for intermediate-risk patients. This article aims to review the most recent results and essential issues.

AB - Purpose of review Transcatheter aortic valve replacement (TAVR) has been effective in prohibitive/high-risk patients. Expansion toward intermediate or even low-risk patients has been proposed. A review of recent developments will help understand current trends and issues. Recent findings The 5-year results from the PARTNER I trial and 2-year results of the CoreValve US Pivotal Trial, together with national registries, confirmed the long-term efficacy and durability of TAVR. Studies including PARTNER II, ADVANCE, and The German Aortic Valve Registry showed short-to mid-term success in intermediate-risk patients. Comparison of balloon-expandable and self-expanding valves in the CHOICE trial associated specific outcome differences with specific valve types, suggesting a more customized approach in valve selection. Short-term results of newer-generation valves have demonstrated excellent safety and efficacy with improved designs. Studies on TAVR-specific complications, such as conduction block and arrhythmia, paravalvular aortic regurgitation, and stroke, have renewed ideas about their prognosis, treatment, and prevention. Conscious sedation percutaneous TAVR has become more popular, with excellent outcomes and improved cost savings. Summary TAVR has been accepted as an effective treatment even for intermediate-risk patients. This article aims to review the most recent results and essential issues.

UR - http://www.scopus.com/inward/record.url?scp=84957431149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957431149&partnerID=8YFLogxK

U2 - 10.1097/HCO.0000000000000260

DO - 10.1097/HCO.0000000000000260

M3 - Review article

C2 - 26808009

AN - SCOPUS:84957431149

VL - 31

SP - 139

EP - 147

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 2

ER -